Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Date publication

juillet 2026

Journal

Cancer treatment and research communications

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Ahrens M, Haanen J, Albiges L, Goupil MG, Boleti E, Gravis G, Fléchon A, Grimm MO, Bedke J, Barthélémy P, Castellano D, Mellado B, Ivanyi P, Rottey S, Flörcken A, Suárez C, Maroto JP, Grünwald V, Oosting S, Kopecky J, Zschäbitz S, Boegemann M, Buchler T, Niegisch G, Goebell PJ, Waddell T, Joly F, Priou F, Retz M, Siemer S, Zimmermann U, Deckbar D, Burkholder I, Stöhr C, Hartmann A, Bergmann L,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42470850

Résumé

Fumarate hydratase (FH)-deficient renal cell carcinoma (RCC) is a rare, molecularly defined subgroup of non-clear cell RCC (nccRCC) lacking an approved standard treatment. We report the exploratory analysis of this entity within the SUNNIFORECAST trial.

Mots clés

Fumarate hydratase (FH)-deficient RCC, Immune checkpoint inhibitors, Ipilimumab, Nivolumab, Non-clear cell renal cell carcinoma, PD-L1 expression, Tyrosine kinase inhibitors

Référence

Cancer Treat Res Commun. 2026 07 18;48:101319